Few adverse effects were reported for the orally administered drug CNV2197944 in both young and elderly patients, indicating that the drug has an “optimal profile for a chronic pain medication,” the company said.
Convergence is currently developing a Phase II trial for the drug.
Related Articles on Pain Management:
RS Medical to Launch Nimbus Radiofrequency Ablation Device
University of New England Researcher Receives $140K Grant to Study Cancer Pain
Memorial Hospital of Union County, Pain Management Group Open Pain Center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.